 This study planned to assess the effect on the reduction in rate of severe asthma exacerbations of different dose levels of QGE031 in asthma patients that are inadequately controlled with inhaled steroid plus beta-2 agonist medication with or without oral steroid. However, this study was terminated due to the efficacy results from an interim analysis at the end of treatment epoch of the Phase II study CQGE031B2201 NCT01716754. Planned data analyses were not performed for this study due to the early termination and the very limited dataset only 10 participants received study medication of the 440 participants planned. 